Provided by Tiger Fintech (Singapore) Pte. Ltd.

Novo-Nordisk A/S

62.55
-4.5500-6.78%
Post-market: 61.56-0.9900-1.58%19:59 EDT
Volume:10.87M
Turnover:689.54M
Market Cap:277.66B
PE:19.91
High:65.47
Open:65.23
Low:62.37
Close:67.10
Loading ...

Stocks to Watch: Eli Lilly, Novo Nordisk, Hims & Hers, Maxeon Solar Technologies

Dow Jones
·
Yesterday

Shares of Obesity Drug Makers Lower, Proposal For Medicare Coverage Dropped

Dow Jones
·
Yesterday

Is Novo Nordisk A/S (NVO) The Best Beaten Down Stock to Buy According to Analysts?

Insider Monkey
·
04 Apr

Novo Nordisk (NVO) Stock Moves -1.67%: What You Should Know

Zacks
·
04 Apr

Artisan Global Opportunities Fund Trimmed its Position in Novo Nordisk A/S (NVO)

Insider Monkey
·
03 Apr

Bernstein Sticks to Its Hold Rating for Novo Nordisk (0QIU)

TIPRANKS
·
03 Apr

Novo Nordisk Details Executive Management Changes

MT Newswires Live
·
03 Apr

Camilla Sylvest to leave Novo Nordisk after 28 years, Bloomberg reports

TIPRANKS
·
03 Apr

Novo Nordisk announces changes in Executive Management

GlobeNewswire
·
03 Apr

Novo Nordisk A/S Stock Falls Wednesday, Underperforms Market

Dow Jones
·
03 Apr

Novo Holdings' earnings nearly doubled in 2024, despite Novo Nordisk's stock slump

Quartz
·
02 Apr

LXRX Stock Moves Up 30% in a Week: What is Driving This Rally?

Zacks
·
02 Apr

Novo Nordisk Stakeholder Reports $9 Billion In Income Due To Robust Weight Loss Drug Sales

Benzinga
·
02 Apr

Novo Nordisk Is a Screaming Buy, AlphaValue Says -- Market Talk

Dow Jones
·
02 Apr

Stocks to Watch Wednesday: Tesla, Newsmax, Novo Nordisk -- WSJ

Dow Jones
·
02 Apr

Novo Resources to Launch RC Drilling at Tibooburra Gold Project

TIPRANKS
·
01 Apr

Novo Nordisk A/S Stock Falls Monday, Outperforms Market

Dow Jones
·
01 Apr

Novo Nordisk Had Constructive Quarter, But U.S. Volumes a Concern -- Market Talk

Dow Jones
·
31 Mar

UBS Remains a Buy on Novo Nordisk (0QIU)

TIPRANKS
·
30 Mar

Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025

GlobeNewswire
·
30 Mar